MANGOCEUTICALS, INC. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 78/100
What the filing says
Mangoceuticals (MGRX, ~$14.7M market cap) received a 180-calendar-day extension from Nasdaq until February 1, 2027 to regain compliance with the $1.00 minimum bid price requirement (10 consecutive business days). The company may execute a reverse stock split if needed. Concurrently, Mangoceuticals is advancing a definitive business combination agreement with Nuclea Energy Inc., a nuclear microreactor developer, which the CEO calls 'transformative' and a pivot from the company's current men's health telemedicine business (MangoRx).
Why this rating
Nasdaq extension buys time but masks critical delisting risk; Nuclea deal is transformational pivot for tiny company—high execution risk, unclear terms, nuclear licensing uncertain. Magnitude and uncertainty justify 78; neutral because extension merely defers crisis while deal remains highly speculative.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.